News

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Mitsubishi UFJ Asset Management Co. Ltd.
Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by ...
GlobalData on MSN5d
Intellia doses first subject in trial of nex-z for hereditary ATTRv-PN
The trial is structured to assess the safety and efficacy of the therapy in approximately 50 ATTRv-PN subjects.
NTLA Stockholders Have Opportunity to Lead Intellia Therapeutics, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
NEW YORK, NY / ACCESS Newswire / April 7, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...
Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication
CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
American Century Companies Inc. Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
American Century Companies Inc. increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 3.5% in ...
Business Insider6d
Intellia Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - NTLA
NEW YORK, NY / ACCESS Newswire / April 2, 2025 / If you suffered a loss on your Intellia Therapeutics, Inc. (NASDAQ:NTLA) investment and want to learn about a potential recovery under the federal ...
Pharmabiz3d
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran
Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran: Cambridge, Massachusetts Saturday, April 5, 2025, 18:00 Hrs [IST] Intellia Therapeu ...